EKF Diagnostics Holdings plc AIM:EKF
- Incorporated
- United Kingdom
- Chief executive
- Gavin Jones
- Employees
- 300
- Reports in
- GBP
- Companies House
- 04347937
Read straight from the annual reports
24.1p at close on 5 Oct 2026 · 11 reported years, 2015–2025
| Line | FY201512/15 | FY201612/16 | FY201712/17 | FY201812/18 | FY201912/19 | FY202012/20 | FY202112/21 | FY202212/22 | FY202312/23 | FY202412/24 | FY202512/25 | FY2026unreported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||
| Gross profit | ||||||||||||
| Operating profit | ||||||||||||
| Exceptional items | ||||||||||||
| Net finance cost | ||||||||||||
| Profit before tax | ||||||||||||
| Tax charge | ||||||||||||
| Profit for the year | ||||||||||||
| EBITDA | ||||||||||||
| Basic EPS | ||||||||||||
| Diluted EPS | ||||||||||||
| Dividend per share | — |
GBP millions, negatives in brackets. Per-share lines in pence, share counts in millions. later is what a following report restated the figure to; vs is a second reading that disagrees. The figure shown is the one the original filing printed, and both readings are kept. Click any figure: opens the report page it was read from, highlighted; shows how it was calculated. The share price above is drawn to the same columns: each close sits over the financial year it fell in.
11 years, at a glance
Dashed: Operating margin, in % on its own scale — read its shape, not its height against the bars.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.
POC Haematology analyser placements and consumable pull-through
POC Hematology revenue £16.6m (2024: £15.8m); analysers sold rose to 16,283 from 9,700. Management says placements should drive future consumable consumption.
page 10Life Sciences β-HB sales (incl. white-label partners)
β-HB revenue £13.8m (2024: £12.5m), up 10%, supported by white-label contracts with Thermo Fisher Scientific and Cardinal Healthcare for β-HB LiquiColor.
page 11Exit from low-margin product groups and clinical chemistry
Gross margin rose to 51% (2024: 48%); gross profit £26.5m (2024: £24.1m). Adjusted EBITDA up 9.3% to £12.4m.
page 13Mix shift toward higher-margin β-HB sales in USA
USA adjusted EBITDA margin improvement attributed to higher β-HB sales and discontinuation of low-margin clinical chemistry.
page 13£330k charge: Business reorganisation: inventory provisions for clinical chemistry (cost of sales)
page 56The trajectory for EKF has been clearly mapped to deliver further improvements in margin, revenue and EBITDA; operational cash generation should be used to invest in areas that build on the strategy.
page 12Between 1 January and 23 March 2026 the Company bought 2,729,000 ordinary shares into treasury at a cost of £0.7m.
page 79The Board has decided to discontinue dividend payments to fund growth in core areas and enhance shareholder value mainly through growth. It will consider recommencing dividends if and when appropriate. No dividends were paid to ordinary shareholders in 2025 or 2024; £362k was paid to non-controlling interests in 2025 (2024: £336k).
page 22Directors' going-concern assessment covers at least 12 months to June 2027 with severe-but-plausible downside scenarios (including reduced US trade and continued Russian cash restrictions); no material uncertainty identified. PwC LLP gave an unmodified opinion dated 24 March 2026; they report no material uncertainty on going concern and no material misstatement in other information.
page 33- Russia: sanctions, Russian Government action and restricted cash (£2.1m); political and operational risk; credit risk on Russian debtorsp.17
- Key employees: loss of staff could damage customer and supplier relationshipsp.17
- Regulatory approvals: products may not get or keep approvals in each territory, and conditions may be too onerousp.18
- Competition from larger multinational diagnostics and pharma companiesp.18
Read from C000413-AR-2025-ch.
10 annual reports read, FY2016 to FY2025
Open a year to see what its report said. Every line in it carries the page it was read from.
Sources: Companies House (10)
FY2026Next report expected 31 Mar 2027